Mellar Davis | Pharmacology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Mellar Davis | Pharmacology | Best Researcher Award

MD FCCP FAAHPM | Levine Cancer Institute | United States

Dr. Mellar Pilgrim Davis, MD, FCCP, FAAHPM, is a distinguished physician specializing in oncology, hematology, and palliative medicine. With decades of experience in clinical practice, research, and education, he has made significant contributions to supportive cancer care. Dr. Davis has held key academic and clinical positions at renowned institutions, impacting patient care and medical education worldwide.

Profile👤

Scopus

Strengths for the Awards✨

  • Extensive Research and Publications 📚

    • Dr. Davis has a prolific research career, with significant contributions in oncology, palliative care, and pain management.
    • Recognized as a World Expert in Analgesics (Top 0.1% of scholars per Expertscape).
    • Highly ranked in Symptomatic Treatment (#4) and Palliative Care (#21) by ScholarGPS.

  • Significant Impact in Palliative Medicine 🌿

    • Held leadership roles in the Multinational Association of Supportive Care in Cancer (MASCC), including Chair of the Pain Subgroup.
    • Developed guidelines and educational programs for pain and opioid management in cancer care.
    • Recognized for outstanding contributions to cancer pain management by MD Anderson Cancer Center (2023).

  • Recognized Excellence in Teaching and Mentorship 🎓

    • Multiple Teacher of the Year awards in Cleveland Clinic and Geisinger.
    • Full Professor of Palliative Medicine at Geisinger Commonwealth School of Medicine.

  • Leadership and Professional Influence 🌍

    • Served on NCI, ASCO, ACS, and NCCN panels, shaping research and clinical practice in oncology and palliative care.
    • Co-Chair of the International Conference on Opioids, advancing pain research.

Education🎓

Dr. Davis earned his Bachelor of Science degree from Otterbein College in 1974 and his MD from Ohio State Medical College in 1977. He further honed his expertise through rigorous postdoctoral training, including an Internal Medicine residency at Riverside Methodist Hospital and a Hematology/Oncology fellowship at Mayo Clinic.

Experience👩‍⚕️

Over the years, Dr. Davis has served in various prestigious medical institutions. His career journey includes roles at Toledo Clinic, Milhon Clinic, Columbus Oncology Associates, Cleveland Clinic, and Geisinger Medical Center. Additionally, he has held academic appointments as a Professor of Medicine at Cleveland Clinic Lerner School of Medicine and as a Professor of Palliative Medicine at Geisinger Commonwealth School of Medicine

Research Interests On Pharmacology

📝 Dr. Davis’s research focuses on palliative medicine, oncology symptom management, pain control, and ethical issues in cancer care. His work has influenced medical guidelines and practices worldwide, especially in the fields of palliative care and supportive oncology.

Awards and Honors🏆

Dr. Davis has received numerous awards, including the Compassion in Medicine Award, multiple “Best Doctors in America” recognitions, and the Distinguished Service Award from the Multinational Association of Supportive Care in Cancer. He has also been acknowledged as a world expert in analgesics and palliative care.

Publications📚

  1. Are Muscle and Fat Loss Predictive of Clinical Events in Pancreatic Cancer? The Importance of Precision Metrics

    • Authors: M.P. Davis, N. Bader, J.L. Basting, B. Lagerman, M.J. Wojtowicz
    • Publication Year: 2025

  2. Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits

    • Authors: M.P. Davis
    • Publication Year: 2025

  3. Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study

    • Authors: M.P. Davis, A.M. Ulrich, R. Segal, B.A. Bauer, C.L. Loprinzi
    • Publication Year: 2024

  4. Respiratory Depression Associated with Opioids: A Narrative Review

    • Authors: M.P. Davis, S.L. DiScala, A. Davis
    • Publication Year: 2024

  5. The Surprise Question: Not Ready for Prime Time

    • Authors: M.P. Davis
    • Publication Year: 2024

  6. Correction to: Opioid Analgesic Dose and Route Conversion Ratio Studies: A Scoping Review to Inform an eDelphi Guideline

    • Authors: M.P. Davis, A.N. Davies, M.L. McPherson, E.D. Bruera, C.I. Ripamonti
    • Publication Year: 2024

  7. Understanding The Number Needed to Treat

    • Authors: M.P. Davis, E.A. Vanenkevort
    • Publication Year: 2024

  8. Opioid Analgesic Dose and Route Conversion Ratio Studies: A Scoping Review to Inform an eDelphi Guideline

    • Authors: M.P. Davis, A.N. Davies, M.L. McPherson, E.D. Bruera, C.I. Ripamonti
    • Publication Year: 2024

  9. Fentanyl Pharmacokinetic Paradoxical in Cancer Cachexia

    • Authors: M.P. Davis
    • Publication Year: 2024

Conclusion🎯

Dr. Mellar Pilgrim Davis has dedicated his career to improving cancer care and palliative medicine. Through his extensive research, clinical expertise, and commitment to education, he has left an enduring impact on patient care and medical knowledge. His legacy continues to inspire healthcare professionals worldwide.

Mei-Lang Kung | Pharmacology | Women Researcher Award

Posted on by sciencefather

Assist. Prof. Dr. Mei-Lang Kung | Pharmacology | Women Researcher Award

Senior Assistant Research Fellow | Kaohsiung Veterans General Hospital | Taiwan

Dr. Mei-Lang Kung is a distinguished researcher and academic specializing in cancer biology, gene engineering, and phytochemical pharmacology. She currently serves as a Senior Assistant Research Fellow at the Department of Medical Education and Research, Kaohsiung Veterans General Hospital, and an Assistant Professor at Shu-Zen Junior College of Medicine and Management. With a strong background in molecular biology and nanomedicine, Dr. Kung has contributed significantly to innovative research in oncology and nanomaterials for medical applications.

Profile👤

ORCID

Scopus

Strengths for the Awards✨

  • Strong Academic Background 📚

    • Dr. Mei-Lang Kung holds a Ph.D. in Biological Science from National Sun Yat-sen University (2012).
    • Her dissertation focused on cancer cell migration and epithelial-mesenchymal transition, a highly relevant area in biomedical research.

  • Extensive Research Expertise 🔬

    • Her work spans multiple interdisciplinary fields, including cancer biology, gene engineering, phytochemical pharmacology, and green nanomaterials.
    • These diverse skill sets enhance the impact of her research in translational medicine.

  • Significant Research Contributions 🏆

    • 21+ peer-reviewed publications in high-impact journals (SCI-indexed).
    • Notable research on nanomedicine and cancer treatment strategies, contributing to innovative therapeutic approaches.
    • Demonstrated leadership as a corresponding author in multiple studies, reflecting independent research capability.

  • Recognition & Awards 🥇

    • Best Poster Award (2021) from the Taiwan Urology Association.
    • National Taiwan University System Young Scholars Award (2018) for innovative research.
    • Multiple Outstanding Paper Awards at prestigious conferences (IEEE, New Advance in Medicine, etc.).
    • These accolades highlight her excellence in research and scholarly impact.

Education 🎓

Dr. Kung earned her Ph.D. in Biological Science from National Sun Yat-sen University, Kaohsiung, Taiwan, in 2012, under the guidance of Prof. Tai Ming-Hong. Her dissertation focused on the mechanisms of hepatoma-derived growth factor-mediated cell migration and epithelial-mesenchymal transition. She also holds an M.S. in Biochemistry from Kaohsiung Medical University (2002) and a B.S. in Nutrition from Chung Shan Medical University (2000).

Experience 🌟

Dr. Kung has extensive experience in academia and research. Since 2019, she has been a Senior Assistant Research Fellow at Kaohsiung Veterans General Hospital. She also holds a faculty position at Shu-Zen Junior College of Medicine and Management. Previously, she served as an Assistant Faculty member (2017-2019) and a Postdoctoral Research Associate (2012-2017) in the Chemistry Department of National Sun Yat-sen University, working under Dr. Shuchen Hsieh.

Research Interests On Pharmacology 📚

Dr. Kung’s research interests include cancer biology, gene engineering, phytochemical pharmacology, and toxicology. She is particularly focused on the development and applications of green nanomaterials for cancer treatment. Her work explores novel phytochemically derived nanoparticles and their effects on cancer cell adhesion, proliferation, and metastasis.

Awards 🏆

  • 2021: Taiwan Urology Association “Best Academic Activity Award – Best Poster Award”
  • 2018: National Taiwan University System Young Scholars Selection for Innovative Research and Development Achievements – Excellent Work Award
  • 2015: New Advance in Generation Medicine, Cancer and Stem Cell Outstanding Paper Award
  • 2013: IEEE Nanotechnology Materials and Devices Conference, Outstanding Paper Award

Publications 📰

Dr. Kung has authored numerous peer-reviewed publications in high-impact journals. Below are some of her notable works:

  1. Wang, J.-H., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2025). “Nanosized ginger-derived phenolic zingerone obstructs cell cycle G2/M progression and initiates apoptosis in human colorectal cancer.” Environmental Toxicology. DOI:10.1002/tox.24470 (SCI; 2023 IF=4.4)
  2. Chu, L.-W., Chen, J.-Y., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2024). “Phytoconstituent-derived zingerone nanoparticles disrupt cell adhesion and suppress cell motility in melanoma B16F10 cells.” Journal of Biotechnology. DOI:10.1016/j.jbiotec.2024.06.015
  3. Kung, M.-L., Cheng, S. M., Wang, Y.-H., et al.* (2024). “Deficiency of RNA adenosine deaminase (ADAR2) ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in male diet-induced obese mice.” Communications Biology. (SCI; 2022 IF=5.9)
  4. Kung, M.-L., Yang, T.-H., Lin, C.-C., et al.* (2024). “ADAR2 deficiency ameliorates nonalcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.” Journal of Cachexia, Sarcopenia and Muscle. DOI:10.1002/jcsm.13460 (SCI; 2022 IF=8.9)
  5. Hu, T.-H., Wu, J.-C., Huang, S.-T., et al.* (2023). “HDGF Stimulates Liver Tumorigenesis by Enhancing Reactive Oxygen Species Generation in Mitochondria.” Journal of Biological Chemistry. (SCI; 2022 IF=4.8)

Conclusion 📚

Dr. Mei-Lang Kung has made remarkable contributions to cancer research and nanomedicine, with a strong emphasis on translating scientific discoveries into therapeutic applications. Her expertise in molecular oncology and green nanotechnology continues to impact the scientific community, making her a leader in the field of biomedical research. Through her innovative work, she strives to advance cancer treatment strategies and improve patient outcomes.